-transparent.png){kind=logo}
The comparative effects of lisinopril, a third generation angiotensin converting enzyme (ACE) inhibitor, on components of the renin-angiotensin system were assessed in normal and in an animal model of diabetes-related hypertension, the streptozotocin-diabetic rat. Two weeks after injection of streptozotocin the mean systolic blood pressure of diabetic rats was elevated 11% above that of normal rats. This effect was prevented by daily injection of insulin. The mean serum ACE activity was elevated 71% above that of normal rats. Lisinopril reduced systolic blood pressure and inhibited serum ACE activity in both normal and diabetic rats in a dose-response fashion. In normal rats maximum inhibition of blood pressure occurred at a mean dose of 1.0 mg/kg and in the diabetic rat at a mean dose of 5.0 mg/kg. At a mean dose of 5 mg/kg, ACE was inhibited by 100 and 92% in normal and diabetic rats, respectively. Plasma renin activity (PRA) increased sharply in both groups of rats treated with the lower doses of lisinopril, only to decrease at the 5 mg/kg level. At 20 mg/kg, PRA continued to decline in normal animals, but not in diabetic rats. Formation of angiotensin II (Ang II) in both normal and diabetic rats was maximally inhibited at doses of 1.0 and 0.1 mg/kg of lisinopril, respectively without a significantly greater effect at the higher doses of the drug. In separate experiments the effects of chronic treatment with lisinopril at two dosage levels on various physiological parameters of streptozotocin-diabetic rats were compared with the effects of another hypotensive agent, hydralazine, an arteriolar vasodilator.(ABSTRACT TRUNCATED AT 250 WORDS)
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
April 2000,
Methods and findings in experimental and clinical pharmacology,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
May 1988,
Drug intelligence & clinical pharmacy,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
January 1989,
Pharmacotherapy,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
September 1988,
Clinical pharmacy,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
May 1992,
The American journal of the medical sciences,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
February 1994,
British journal of pharmacology,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
January 1993,
Acta diabetologica,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
April 1986,
Journal of pharmaceutical sciences,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
January 2018,
International journal of retina and vitreous,
J F Hartmann, and
M Szemplinski, and
N S Hayes, and
M E Keegan, and
E E Slater
September 1993,
Journal of cardiovascular pharmacology,
